key: cord-0962682-x3tdd73s
authors: Mehalko, Jennifer; Drew, Matthew; Snead, Kelly; Denson, John-Paul; Wall, Vanessa; Taylor, Troy; Sadtler, Kaitlyn; Messing, Simon; Gillette, William; Esposito, Dominic
title: Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays
date: 2020-11-25
journal: Protein Expr Purif
DOI: 10.1016/j.pep.2020.105802
sha: 04b23582eaede04c7d4827a498cf1bf66be59ce6
doc_id: 962682
cord_uid: x3tdd73s

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a commonly used antigen for serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Different versions of the RBD protein have been developed and utilized in assays, with higher sensitivity attributed to particular forms of the protein. To improve the yield of these high-sensitivity forms of RBD and support the increased demand for this antigen in serology assays, we investigated several protein expression variables including DNA elements such as promoters and signal peptides, cell culture expression parameters, and purification processes. Through this investigation, we developed a simplified and robust purification strategy that consistently resulted in high levels of the high-sensitivity form of RBD and demonstrated that a carboxyterminal tag is responsible for the increased sensitivity in the ELISA. These improved reagents and processes produce high-quality proteins which are functional in serology assays and can be used to investigate seropositivity to SARS-CoV-2 infection.

Serology assays are critical tools in the response to the COVID-19 pandemic [1] . Such 56 assays can measure the presence and extent of an immune response and help to identify the 57 number of asymptomatic SARS-CoV-2 infections in the population. Until an effective vaccine is 58 developed, these are critical tools in identifying and controlling the spread of the infection. A 59 number of serology assays have been published to date, with many employing subdomains of the 60 SARS-CoV-2 S protein (hereafter referred to as spike) in ELISA-based assays. The specificity of 61 the spike protein [1, 2] makes it a clear target for therapeutic interventions such as vaccines or 62 monoclonal antibodies, and also for use in serology studies to assess the prevalence of immune 63 responses to the virus and therapeutics. In addition to soluble spike trimer, receptor binding 64 domain (RBD) is also frequently utilized in these assays [3, 4] . RBD, which interacts with the extracellular ACE2 receptor and permits entry of SARS-CoV-2 into cells, is considerably 66 smaller and more readily generated in recombinant form than the full-length spike. While 67 modified production methods have improved the production of soluble full-length spike protein 68 [5] , RBD production optimization has lagged. Recently, during development of assays to 69 support an NIH-led serosurvey, it was shown that certain forms of RBD resulted in higher 70 sensitivity ELISA results [6] , presumably due to higher antibody affinity. To explore this further, 71 and to optimize production of various RBD reagents, we investigated multiple protein constructs 72 for protein production yield and their impact on the sensitivity of serology assays. This work 73 allowed us to improve the production yield of the most sensitive form of RBD by modifying 74 DNA sequence of the expression vectors, cell culture temperature and harvest time, and 75 purification methodology. The final proteins produced were highly pure and functioned as 76 J o u r n a l P r e -p r o o f 4 sensitive and specific antigens in ELISAs. Our data also shows that improvements in serology 77 assay sensitivity are caused by the addition of a carboxy-terminal streptavidin-binding protein 78 (SBP) tag [7] , which likely helps orient the protein on ELISA plates for better antibody 79 detection. Taken together, these improvements allowed the production of sufficient RBD antigen 80 for more than 6,000 ELISA plates per liter of culture. Inc.). Entry clones were subcloned using Multisite Gateway recombination (ThermoFisher) into 91 pDest-303 (Addgene #159678) with an optimized CMV51 promoter [8] . Final expression clones 92 were validated by restriction analysis. The similarities and differences in these constructs are 93 outlined in Table 1 and shown schematically in Fig. 1 

To produce SARS-CoV-2 RBD for the development of serology assays, we initially 204 tested two constructs previously published in the literature [3, 4] . Initial findings showed that the 205 construct from the Ragon Institute, although containing less spike protein sequence, resulted in 206 more than a 2-fold higher sensitivity in ELISA assays than the Mt. Sinai version of the protein 207 [6] . However, the Ragon protein production yield was considerably lower than that of the Mt. are highlighted in Fig. 1 , and details about their construction are noted in Table 1 .

Optimization of protein expression and purification 232 Previously, we had optimized production of SARS-CoV-2 soluble spike protein using the 233 Expi293 expression system with reduced temperature to enhance protein secretion [5] . A similar 234 strategy was employed with RBD proteins, using a 32°C expression for 96 hours to maximize 235 production while maintaining high levels of cell viability. We investigated whether longer 236 incubation might also enhance protein yield, but harvest at 120 hours post-transfection did not 237 improve production, and in some cases, may have actually reduced final yields (data not shown).

Published protocols for purification of RBD domains often utilize a batch process, which 239 generally is less efficient than column chromatography. For this reason, we developed a 240 modified approach to that used for soluble spike production, including an initial tangential flow 241 filtration step to buffer exchange and concentrate the initial supernatant, followed by a column 242 IMAC process with a gradient elution. Protein was subsequently concentrated and applied to a 243 size exclusion column for final polishing. In general, all constructs performed similarly in this 244 process regardless of expression level, and all protein was readily captured by the IMAC resin.

A typical purification is shown in Fig. 2A Coomassie staining of glycoproteins it is difficult to assess overall recovery, but given the lack of 249 detectable RBD in the flowthrough, we expect the overall yield of the process is consistently 250 >75%.

Final proteins from one complete set of purifications are shown in Fig. 2C , and a 252 summary of purification yields from multiple independent productions of each protein are 253 highlighted in Table 2 . From this data, it is clear that yields from our optimized vector system 254 are higher than either original construct. In the case of the Sinai protein, the yield improvement containing M69 protein was similar to that of the M67 Sinai construct-all of these proteins are 259 nearly identical in size and amino acid sequence and would be expected, under optimal 260 conditions, to produce similar levels of protein. If the SBP-containing M68 is corrected for the 261 larger mass of the fusion protein, the 63.6 mg/l yield is effectively the same molar productivity 262 as the other constructs, again suggesting that these RBD proteins are being produced at similar 263 levels regardless of construct details. Fig. 2C also highlights the glycosylation observed on the 264 purified RBD proteins, as clearly noted by the smeared appearance of the purified proteins. 265 After treatment with PNGase F to remove N-linked glycans known to be present in spike at 266 Asn331 and Asn343, the proteins migrate at a more appropriate molecular weight on the SDS-267 PAGE gel and with a more defined appearance. Performance of proteins in serology assays 306 We have previously developed and optimized a serology assay using an ELISA format 307 [6] , which showed that the Ragon version of RBD was more sensitive than the Sinai version. To 308 identify what components of our newly produced RBD proteins might lead to this higher ELISA 309 sensitivity, we compared all of the proteins in the serology assay. Fig. 4 there is a specific feature of this tag which uniquely results in greater sensitivity. In any case, we 320 demonstrate here that the presence of the SBP tag on these constructs significantly improves 321 sensitivity of the assay, making it the optimal choice for use in SARS-CoV-2 serology efforts. 322 We also compared the performance of X24 protein purified using the standard purification 

In summary, we presented multiple improvements to the production of SARS-CoV-2 335 RBD that increase the ability of laboratories to generate this high-quality vital reagent for 336 serology assays and other applications. In particular, we confirmed that the SBP tag present on 337 the Ragon RBD construct makes it more attractive as a serology assay substrate due to the higher 338 level of sensitivity. Additional work needs to be done to clarify the specific role of SBP in the 339 process. Deployment of this reagent for serology assays to determine the prevalence of SARS- 

Serology assays to manage COVID-19

Ultrasensitive high-resolution profiling of early seroconversion 426 in patients with COVID-19

CoV-2 soluble spike trimers for serology assays

Standardization of enzyme-436 linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and 437 at-home blood sampling

One-step purification of recombinant 440 proteins using a nanomolar-affinity streptavidin-binding peptide, the SBP-Tag

Combinatorial assembly of 444 clone libraries using site-specific recombination